Inicio/Acciones/RLMD

RLMD

USD

Relmada Therapeutics Inc. Common Stock

$2.770+0.560 (25.339%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$2.210

Máximo

$2.810

Mínimo

$2.190

Volumen

0.98M

Fundamentos de la Empresa

Capitalización de Mercado

91.9M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.74M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $0.24Actual $2.770Máximo $3.5

Noticias Relacionadas

4 nov 2025 · 12:09

GlobeNewswire

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

4 nov 2025 · 12:01

GlobeNewswire

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized